Adocia SA (ADOC.PA)
EUR 6.39
(1.59%)
EUR 6.39
(1.59%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 2.15 Million EUR | -81.22% |
| 2022 | 11.44 Million EUR | 692.73% |
| 2021 | 1.44 Million EUR | 71.7% |
| 2020 | 841 Thousand EUR | -60.76% |
| 2019 | 2.14 Million EUR | -95.48% |
| 2018 | 47.38 Million EUR | 143.41% |
| 2017 | 19.46 Million EUR | -13.42% |
| 2016 | 22.48 Million EUR | -39.12% |
| 2015 | 36.93 Million EUR | 5146.59% |
| 2014 | 704 Thousand EUR | -87.4% |
| 2013 | 5.58 Million EUR | 39.86% |
| 2012 | 3.99 Million EUR | 157.64% |
| 2011 | 1.55 Million EUR | 1297.3% |
| 2010 | 111 Thousand EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | - EUR | 0.0% |
| 2023 Q2 | 1.62 Million EUR | -16.59% |
| 2023 Q3 | 1.07 Million EUR | -33.99% |
| 2023 Q4 | 523 Thousand EUR | -51.3% |
| 2023 Q1 | 1.95 Million EUR | -52.4% |
| 2023 FY | 2.15 Million EUR | -81.22% |
| 2022 Q1 | 5.2 Million EUR | 399.9% |
| 2022 Q2 | 7.34 Million EUR | 41.08% |
| 2022 Q3 | 3.47 Million EUR | -52.76% |
| 2022 Q4 | 4.09 Million EUR | 18.05% |
| 2022 FY | 11.44 Million EUR | 692.73% |
| 2021 Q1 | 1.26 Million EUR | 477.17% |
| 2021 Q3 | 1.76 Million EUR | 338.68% |
| 2021 Q4 | 1.04 Million EUR | -40.91% |
| 2021 FY | 1.44 Million EUR | 71.7% |
| 2021 Q2 | 402 Thousand EUR | -68.2% |
| 2020 FY | 841 Thousand EUR | -60.76% |
| 2020 Q1 | 1.78 Million EUR | 312.47% |
| 2020 Q2 | 622 Thousand EUR | -65.17% |
| 2020 Q4 | 219 Thousand EUR | -86.57% |
| 2020 Q3 | 1.63 Million EUR | 162.14% |
| 2019 Q2 | 1.71 Million EUR | -28.06% |
| 2019 FY | 2.14 Million EUR | -95.48% |
| 2019 Q4 | 433 Thousand EUR | -74.39% |
| 2019 Q3 | 1.69 Million EUR | -1.14% |
| 2019 Q1 | 2.37 Million EUR | -73.33% |
| 2018 Q1 | 18.05 Million EUR | 790.16% |
| 2018 Q4 | 8.91 Million EUR | 0.0% |
| 2018 FY | 47.38 Million EUR | 143.41% |
| 2018 Q3 | 8.91 Million EUR | -50.63% |
| 2018 Q2 | 18.05 Million EUR | 0.0% |
| 2017 FY | 19.46 Million EUR | -13.42% |
| 2017 Q4 | 2.02 Million EUR | 0.0% |
| 2017 Q3 | 2.02 Million EUR | -82.46% |
| 2017 Q2 | 11.56 Million EUR | 0.0% |
| 2017 Q1 | 11.56 Million EUR | 58.81% |
| 2016 Q2 | 7.94 Million EUR | 0.0% |
| 2016 Q3 | 7.27 Million EUR | -8.41% |
| 2016 Q1 | 7.94 Million EUR | -43.39% |
| 2016 Q4 | 7.27 Million EUR | 0.0% |
| 2016 FY | 22.48 Million EUR | -39.12% |
| 2015 Q4 | 14.03 Million EUR | 0.0% |
| 2015 FY | 36.93 Million EUR | 5146.59% |
| 2015 Q3 | 14.03 Million EUR | 68.4% |
| 2015 Q2 | 8.33 Million EUR | 0.0% |
| 2015 Q1 | 8.33 Million EUR | 628.44% |
| 2014 Q1 | 937 Thousand EUR | -69.19% |
| 2014 Q3 | 1.14 Million EUR | 22.15% |
| 2014 Q4 | 1.14 Million EUR | 0.0% |
| 2014 FY | 704 Thousand EUR | -87.4% |
| 2014 Q2 | 937 Thousand EUR | 0.0% |
| 2013 Q1 | 1.36 Million EUR | -12.46% |
| 2013 Q2 | 1.36 Million EUR | 0.0% |
| 2013 Q3 | 3.04 Million EUR | 122.09% |
| 2013 Q4 | 3.04 Million EUR | 0.0% |
| 2013 FY | 5.58 Million EUR | 39.86% |
| 2012 FY | 3.99 Million EUR | 157.64% |
| 2012 Q4 | 1.56 Million EUR | 0.0% |
| 2012 Q3 | 1.56 Million EUR | 0.0% |
| 2011 FY | 1.55 Million EUR | 1297.3% |
| 2010 FY | 111 Thousand EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| ABIONYX Pharma SA | 4.64 Million EUR | 53.664% |
| ABIVAX Société Anonyme | 4.62 Million EUR | 53.473% |
| Aelis Farma SA | 9.05 Million EUR | 76.254% |
| Biophytis S.A. | - EUR | -Infinity% |
| Advicenne S.A. | 3.15 Million EUR | 31.768% |
| genOway Société anonyme | 20.04 Million EUR | 89.275% |
| IntegraGen SA | 12.53 Million EUR | 82.851% |
| Medesis Pharma S.A. | 300.03 Thousand EUR | -616.585% |
| Neovacs S.A. | 533.41 Thousand EUR | -303.066% |
| NFL Biosciences SA | - EUR | -Infinity% |
| Plant Advanced Technologies SA | 1.68 Million EUR | -27.861% |
| Quantum Genomics Société Anonyme | 19.79 Thousand EUR | -10760.78% |
| Sensorion SA | 4.74 Million EUR | 54.671% |
| Theranexus Société Anonyme | 296.33 Thousand EUR | -625.54% |
| TME Pharma N.V. | 17 Thousand EUR | -12547.059% |
| Valbiotis SA | 4.73 Million EUR | 54.574% |
| TheraVet SA | 1.07 Million EUR | -99.433% |
| Valerio Therapeutics Société anonyme | 1.8 Million EUR | -19.444% |
| argenx SE | 1.13 Billion EUR | 99.81% |
| BioSenic S.A. | 543 Thousand EUR | -295.948% |
| Celyad Oncology SA | 102 Thousand EUR | -2007.843% |
| DBV Technologies S.A. | - EUR | -Infinity% |
| Galapagos NV | 239.72 Million EUR | 99.103% |
| Genfit S.A. | 28.56 Million EUR | 92.473% |
| GeNeuro SA | - EUR | -Infinity% |
| Hyloris Pharmaceuticals SA | 2.08 Million EUR | -3.019% |
| Innate Pharma S.A. | 51.9 Million EUR | 95.857% |
| Inventiva S.A. | 17.47 Million EUR | 87.698% |
| MaaT Pharma SA | 2.22 Million EUR | 3.501% |
| MedinCell S.A. | 9.16 Million EUR | 76.528% |
| Nanobiotix S.A. | 30.05 Million EUR | 92.847% |
| Onward Medical N.V. | 532 Thousand EUR | -304.135% |
| Oryzon Genomics S.A. | 14.19 Million EUR | 84.85% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | 3.458% |
| Oxurion NV | 263 Thousand EUR | -717.49% |
| Pharming Group N.V. | 245.31 Million EUR | 99.124% |
| Poxel S.A. | 1.98 Million EUR | -8.531% |
| GenSight Biologics S.A. | 1.26 Million EUR | -69.692% |
| Transgene SA | 1.18 Million EUR | -81.588% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 5.25 Billion EUR | 99.959% |
| Valneva SE | 153.71 Million EUR | 98.601% |
| Vivoryon Therapeutics N.V. | -3.62 Million EUR | 159.392% |